Peptron Eyes Differentiation As Exenatide Progresses For Parkinson’s

While the peptide-based therapeutics space is getting increasingly crowded, Peptron Inc., which has decades of experience in peptide research, is aiming to differentiate itself with proprietary technology that improves convenience for patients and potentially raises therapeutic efficacy.

"Very few companies are developing long-acting formulations, and, as far as we know, we are the only company developing sustained release-exenatide for a neurodegenerative treatment," said Hyosup Kim, director of business development of Peptron, in a recent interview with Scrip